U.S. STOCKS ON THE MOVE-Arlington Asset Investment, Redwoods, GreenLight Biosciences
Genprex up on safety committee's nod for mid-stage study for lung cancer therapy
Brief: Genprex Receives Safety Review Committee Approval To Advance To Phase 2 Expansion Portion Of Acclaim-1 Clinical Trial Of Reqorsa® In Combination With Tagrisso® In Advanced Non-Small Cell Lung Cancer
U.S. STOCKS ON THE MOVE-Coherent, Copper miners, US banks
U.S. STOCKS ON THE MOVE-Ulta Beauty, Paramount Global, Microsoft
Genprex rises on encouraging early-stage data on lung cancer therapy
U.S. STOCKS ON THE MOVE-Marvell Technology, Tilray, Workday
U.S. STOCKS ON THE MOVE-Ford Motor, Gap, Moderna
Genprex up on encouraging early-stage data on lung cancer therapy
Brief: Genprex Publishes Positive Clinical Data From Phase 1 Portion Of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy In Non-Small Cell Lung Cancer At 2023 ASCO Annual Meeting
Brief: Genprex Inc Files For Mixed Shelf Of Up To $200 Million
Brief: Genprex CEO Commends FDA's Initiative To Accelerate Approval Process For Gene Therapies
Brief: Genprex Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank, Does Not Otherwise Have A Business Relationship With Silicon Valley Bank
Brief: Genprex Announces $4 Million Registered Direct Offering With A Single, Healthcare-Focused Institutional Investor
U.S. STOCKS ON THE MOVE-Vascular Biogenics, Apellis Pharma, Nikola
U.S. STOCKS ON THE MOVE-Netflix, General Motors, Graphite Bio
Genprex rises as diabetes therapy shows promise in animal study
Brief: Genprex Announces Data From Non-Human Primate Study Evaluating Novel Gene Therapy To Treat Type 1 Diabetes
Brief: Genprex Signs License To Additional Diabetes Technology With University Of Pittsburgh